537

Towards a New Type of Aromatic Diynes Activation : Synthesis of a Novel Bicyclic Enediyne

Stéphane Raeppel, Dominique Toussaint and Jean Suffert*

Laboratoire de Pharmacochimie de la Communication Cellulaire, Université Louis Pasteur,

Faculté de Pharmacie, ERS 655 du CNRS - 74, route du Rhin - BP 24 - F-67401 Illkirch Cedex - France

Fax (33) 3 88 67 47 94 ; e-mail jeansu@pharma.u-strasbg.fr

Received 4 February 1998

Abstract : The aromatic acyclic diynes 2 and 3 have been synthesised in order to test the feasibility of a new activation towards their cyclisation. In addition, a difference of stability between 13 and 20 during the Nozaki-Kishi cyclisation reaction occurs when the aromatic ring possesses or not an intramolecular trigger device. Thus, the aromatic bicyclic enediyne 14 is stable while 21 has not been isolated.

In our endeavour for the synthesis of cyclic enediynes¹ and dienediynes,² analogs of the potent antitumor natural products³, we considered applying the prodrug concept⁴ to our target molecules in order to stabilize these strongly labile compounds. Thus, we proposed a new type of activation of acyclic diynes bearing an aromatic moiety. The first step would be an intermolecular activation of the prodrug followed by the intramolecular trigger device release⁵ (e.g., electron-donating group as illustrated in molecule **5**) with the aim of generating an activated species. The second step would be the addition of a nucleophile to the activated species to give rise to a diradical through a Saito/Myers cycloaromatisation.⁶ This cascade reaction would allow us to reach our objective. In a preliminary study, we planned to illustrate this mode of activation on simple model compounds (Scheme 1).



Scheme 1. a) TMSC=CH (1.3 equiv.), Pd(PPh₃)₂Cl₂ (5 mol-%), Cul (10 mol-%), PhH, Et₃N, RT, 30 min, 96%; b) TMSC=CLi (1.3 equiv.), THF, hexane, -78° C, 1 h, 59%; c) NH₄F (50 equiv.), *n*-Bu₄NHSO₄ (0.2 equiv.), CH₂Cl₂, H₂O, RT, 1 h, 95%; d) Ac₂O (2 equiv.), 1,4-cyclohexadiene (10 equiv.), pyridine (20 equiv.), 4-DMAP (5 mol-%), CH₂Cl₂, RT, 5 min, decomposition; e) Ac₂O (2 equiv.), 1,4-cyclohexadiene (10 equiv.), 4-DMAP (5 mol-%), CH₂Cl₂, RT, 5 min, decomposition; e) Ac₂O (2 equiv.), 1,4-cyclohexadiene (10 equiv.), 4-DMAP (5 mol-%), CH₂Cl₂, RT, 4 h, then NaBH₃CN (1 equiv.), CH₃CN, H₂O, RT, 30 min, 26% for 4

Thus, the compounds 2 and 3 were synthesised from 1 in order to investigate the feasibility of the process. Palladium catalysed cross-coupling⁷ between 1 and (trimethylsilyl)acetylene is followed by the lithium (trimethylsilyl)acetylide addition to the aldehyde. The acyclic diyne 2 yielded 3 after full desilylation.⁸ These compounds (2,3) proved to be fairly stable. When 3 was subjected to acylation, it was completely consumed and only decomposition was observed after a few minutes (TLC control). In contrast to compound 3, 2 reacted slowly, (probably because of steric hindrance between both trimethylsilyl groups on the two terminal alkynes) and 4 was isolated after reduction

in 26% yield. In view of this result, acylation of **2** (intermolecular activation) may lead to **5**, which can liberate an acetate molecule owing to the release of the intramolecular trigger device (dimethylamino), and generate two possible intermediates [(*E*)-conformer **6** + (*Z*)-conformer **7**]. Unfortunately, we were not able to isolate any products which would result from a Saito/Myers cycloaromatisation (Scheme 2), even in the presence of a radical scavenger.



Thereafter, we have intended to apply this new type of activation to the cyclic enediynes 21 in order to favor the cycloaromatisation process by blocking the two acetylenic arms in a rigid cyclic system which would eventually lead to a strong interaction between the two triple bonds. In a first step, 13 was synthesised in order to study the sensitive cyclisation key step. Compound 13 was obtained from 8^9 and 10^{10} by convergent synthesis (Scheme 3). First, ester reduction of 8 to the aldehyde ("tear oil" unstable) with Dibal-H and addition of TMSC=CCeCl₂¹¹ followed by silvlation of the alcohol with TBDPSCl gave envne 9 in 68% yield (three steps). Reduction of 10 with NaBH₄ in ethanol and desilylation by phase transfer catalysis with ammonium fluoride⁸ gave 11 in 80% yield (two steps). Palladium catalysed cross-coupling⁷ between 9 and 11 produced aromatic acyclic enediyne 12 in very good yield. Selective monodesilylation of 12 with K2CO3 in methanol and iodination12 with the presence of morpholine, followed by benzyl alcohol oxidation, using the Dess-Martin periodinane¹³ afforded 13 in 80% yield (3 steps). Finally, the ring closure of 13 according to the Nozaki-Kishi reaction¹⁴ by employing the conditions described by Eckhardt-Brückner^{12b} allowed us to isolate 14 in 37% yield as a 1/1 inseparable diastereomeric



Scheme 3 . a) Dibal-H (1.05 equiv.) in toluene, CH_2CI_2 , $-78^{\circ}C$, 30 min; b) TMSC=CCeCl₂ (1.3 equiv.), THF, hexane, $-78^{\circ}C$, 2 h, 68% (two steps); c) TBDPSCI (1.1 equiv.), imidazole (2.2 equiv.), DMF, 0°C, 2h, 100%; d) NaBH₄ (1.1 equiv.), EtOH, 0°C, 20 min; e) NH₄F (50 equiv.), *n*-Bu₄NHSO₄ (0.15 equiv.), CH₂Cl₂, H₂O, RT, 1 h, 80% (two steps); f) 9 (1.0 equiv.), 11 (1.2 equiv.), Pd(PPh₃)₂Cl₂ (5 mol-%), Cul (15 mol-%), THF, *i*-Pr₂NH, RT, 2 h, 95%; g) K₂CO₃ (20 mol-%), MeOH, RT, 4 h, 95%; h) I₂ (3 equiv.), morpholine (9 equiv.), THF, 50°C, 5 h, 94%; i) Dess-Martin periodinane (1.3 equiv.), CH₂Cl₂, 0°C, 1 h at RT, 90%; j) CrCl₂ (3 equiv.), NiCl₂ (1 equiv.), THF, RT, 2 h, 37% (1/1 diastereoisomeric mixture)



Scheme 4 . a) activated MnO₂ (10 equiv.), CH_2Cl_2 , RT, 16 h; b) TMSC=CLi (2.2 equiv.), THF, hexane, $-78^{\circ}C$, 15 min, 49% (two steps); c) TBDMSCI (1.5 equiv.), imidazole (2.0 equiv.), THF, RT, 12 h, 95%; d) HCHO 37% in water (10 equiv.), NaBH₃CN (3 equiv.), CH₃CN, AcOH, RT, 3 h, 93%; e) POCl₃ (1.2 equiv.), DMF, 75°C, 3 h, 82%; f) 16 (1.2 equiv.), 1 (1.0 equiv.), Pd(PPh₃)₂Cl₂ (5 mol-%), Cul (10 mol-%), PhH, Et₃N, RT, 1 h, 98%; g) K₂CO₃ (30 mol-%), MeOH, CH₂Cl₂, RT, 6 h; h) NaBH₄ (1.6 equiv.), EtOH, THF, RT, 4 h, 90% (two steps); i) I₂ (3 equiv.), morpholine (9 equiv.), THF, 45°C, 14 h, 65%; j) TPAP (5 mol-%), NMO, monohydrate (1.5 equiv.), MS 4Å, CH₂Cl₂, RT, 1 h, 95%

In the same way, **20** was obtained from **15** and **17** by convergent synthesis (Scheme 4). Commercially available allylic alcohol **15** was oxidized with activated MnO_2^{15} to the aldehyde (very volatile and unstable) which immediately reacted subsequently with lithium trimethylsilylacetylide, and protected as a silylated ether to give **16** in

47% yield (three steps). Furthermore, dimethylation¹⁶ of **17**, followed by a regioselective formylation¹⁷ step, yielded iodo arene **1** in 76% yield (two steps). Palladium catalysed cross-coupling⁷ between **16** and **1** afforded **18** in very good yield.

Desilylation of the alkyne with K_2CO_3 in methanol/dichloromethane (2/1) and reduction of the aldehyde with NaBH₄ in ethanol/THF (2/1) furnished the intermediate **19** in 90% yield (two steps). Finally, iodination¹² with the presence of morpholine and benzylic alcohol oxidation with TPAP¹⁸ and NMO gave the acyclic enediyne **20**¹⁹ in 62% yield (two steps), precursor of bicycle **21**. Unfortunately, the ring closure carried out following the conditions used for **13** led after several attemps to a complex mixture of unidentified compounds. Probably the cyclisation step occurs, however the trigger device must be activated and releases a reaction cascade.

In conclusion, a new type of aromatic acyclic diynes activation was conceived and tested on model substrates. Studies towards the synthesis and the activation in presence of a nucleophile (e. g., thiol) of these simple aromatic acyclic diynes are in progress and will be reported in due course.

References and Notes

- a) Suffert, J. *Tetrahedron Lett.* **1990**, *31*, 7437-7440. b) Suffert, J.; Toussaint, D. *Tetrahedron Lett.* **1997**, *38*, 5507-5510. c) Toussaint, D. PhD thesis, University Louis Pasteur of Strasbourg (France), **1996**.
- (2) a) Eckhardt, M.; Brückner, R.; Suffert, J. *Tetrahedron Lett.* 1995, 36, 5167-5170. b) Suffert, J.; Abraham, E.; Raeppel, S.; Brückner, R. *Liebigs Ann.* 1996, 447-456. c) Brickmann, K.; Hambloch, F.; Suffert, J.; Brückner, R. *Liebigs Ann.* 1996, 457-471.
- (3) Reviews : a) Nicolaou, K. C.; Dai, W. M. Angew. Chem., Int. Ed. Engl. 1991, 30, 1387-1416; Angew. Chem. 1991, 103, 1453-1481.
 b) Lhermitte, H.; Grierson, D. S. Cont. Org. Synth. 1996, 3, 41-63; *ibid.* 1996, 3, 93-124.
- (4) Maier, M. E. Synlett 1995, 13.
- (5) Mastalerz, H.; Doyle, T. W.; Kadow, J. F.; Vyas, D. M. *Tetrahedron Lett.* **1996**, *37*, 8683-8686.
- (6) a) Myers, A. G.; Proteau, P. J. J. Am. Chem. Soc. 1989, 111, 1146-1147. b) Nagata, R.; Yamanaka, H.; Okazaki, E.; Saito, I. *Tetrahedron Lett.* 1980, 21, 217-220.
- Sonogashira, K.; Tohda, Y.; Hagihara, N. *Tetrahedron Lett.* 1975, 4467-4410.
- (8) Herold, P. Helv. Chem. Acta 1988, 71, 354-362.
- (9) Marek, I.; Alexakis, A.; Normant, J.-F. *Tetrahedron Lett.* 1991, 32, 5329-5332.
- (10) Austin, W. B.; Bilow, N.; Kelleghan, W. J.; Lau, K. S. Y. J. Org. Chem. 1981, 46, 2280-2286.
- (11) Imamoto, T.; Sugiura, Y.; Takaiyama, N. *Tetrahedron Lett.* 1984, 25, 4233-4236.
- (12) a) Southwick, P. L.; Kirchner, J. R. J. Org. Chem. 1962, 27, 3305-3308. b) Eckhardt, M.; Brückner, R. Liebigs Ann. 1996, 473-488.
- (13) Dess, D. B.; Martin, J. C. J. Org. Chem. 1983, 48, 4155-4156.
- (14) a) Takai, K.; Tagashira, M.; Kuroda, T.; Oshima, K.; Utimoto, K.; Nozaki, H. J. Am. Chem. Soc. **1986**, 108, 6048-6050. b) Jin, H.; Uenishi, J.; Christ, W. J.; Kishi, Y. J. Am. Chem. Soc. **1986**, 108, 5644-5646. c) Crevisy, C.; Beau, J.-M. Tetrahedron Lett. **1991**, 32, 3171-3174.
- (15) Goldman, I. M. J. Org. Chem. 1969, 34, 1979-1981.

- (16) Borch, R. F.; Hassid, A. I. J. Org. Chem. 1972, 37, 1673-1674.
- (17) Ask, A.-L.; Ögren, S.-O.; Ross, S. B. J. Med. Chem. 1978, 21, 56-63.
- (18) Griffith, W. P.; Ley, S. V.; Whitcombe, G. P.; White, A. D. J. Chem. Soc., Chem. Commun. **1987**, 1625-1627.
- (19) All new compounds are characterized by ¹H and ¹³C NMR, and microanalysis.

13 : ¹**H NMR** (CDCl₃ - 200 MHz) : δ = 1.08 [s, 9H, SiC (C<u>H</u>₃)₃], 5.50 (d, 1H, ³*J* = 8.8 Hz, H-5"), 5.77 (d, 1H, ³*J* = 10.5 Hz, H-3"), 6.09 (dd, 1H, ³*J* = 10.5 Hz, ³*J* = 8.8 Hz, H-4"), 7.12-7.69 [m, 10H, Si(<u>Ph</u>)₂], 7.72-7.90 (m, 4H, aromatic H), 10.13 (s, 1H, H-1). -¹³C **NMR** (CDCl₃ - 50 MHz) : δ = 3.65 (C-7"), 19.26 [Si<u>C</u>(CH₃)₃], 26.49 [SiC(<u>C</u>H₃)₃], 63.40 (C-5"), 90.93-91.11-93.14 (C-1", 2", 6"), 109.53 (C quat), 126.18-126.95-127.57-128.71-129.77 (CH), 132.75 (C quat), 133.38-133.45 (CH), 135.69 (C quat), 135.88-142.01 (CH), 191.08 (C-1). – **microanalysis** : % C (th. = 62.72, exp. = 62.81), % H (th. = 4.74, exp. = 4.87).

14 : ¹**H NMR** (CDCl₃ - 200 MHz) : $\delta = 1.09$ [s, 9H, SiC (C<u>H</u>₃)₃, dia I], 1.11 [s, 9H, SiC(C<u>H</u>₃)₃, dia II], 2.13 (d, 1H, ³*J* = 7.1 Hz, OH, dia I), 2.20 (d, 1H, ³*J* = 7.6 Hz, OH, dia II), 5.09 (m, 1H, H-8, dia I), 5.17 (m, 1H, H-8, dia II), 5.23 (d, 1H, ³*J* = 7.6 Hz, H-1, dia II), 5.40 (dd, 1H, ³*J* = 7.1 Hz, ⁵*J* = 1.7 Hz, H-1, dia I), 5.75 (d, 1H, ³*J* = 11.7 Hz, H-6, dia I), 5.76 (d, 1H, ³*J* = 11.7 Hz, H-6, dia I), 5.88 (dd, 1H, ³*J* = 11.7 Hz, ³*J* = 3.8 Hz, H-7, dia I), 5.98 (dd, 1H,

 ${}^{3}J = 11.7$ Hz, ${}^{3}J = 2.7$ Hz, H-7, dia II), 7.13-7.49 [m, 10H, Si(<u>Ph</u>)₂], 7.66-7.90 (m, 4H, aromatic H). – ${}^{13}C$ NMR (CDCl₃ - 50 MHz) : $\delta = 19.22$ [SiC(CH₃)₃], 26.82 [SiC(<u>C</u>H₃)₃], 62.44-62.85 (C-8), 64.21-65.53 (C-1), 85.10-86.28-91.45-95.78 (C-4, 5, 9, 10), 109.78-110.55 (CH), 120.74-121.07 (C quat), 127.53-127.73-128.02-128.31-128.82-128.93-129.91-130.14-131.82 (CH), 133.09-133.17 (C quat), 134.77-135.80-136.02 (CH), 139.11 (C quat), 139.59-141.62 (CH). – **MS**, m/z (%) : 448 (26) [M⁺], 391 (84), 314 (47), 252 (48), 199 (100).

- microanalysis : % C (th. = 76.10, exp. = 75.97), % H (th. = 6.97, exp. = 7.22).

20 : ¹**H NMR** (CDCl₃ - 200 MHz) : $\delta = 0.15 \cdot 0.17$ [2 s, 6H, Si(CH₃)₂], 0.92 [s, 9H, SiC(CH₃)₃], 2.01 (d, 3H, ⁴*J* = 1.3 Hz, CH₃), 3.10 [s, 6H, N(CH₃)₂]; 5.54 (d, 1H, ³*J* = 8.8 Hz, H-5"), 5.85 (dq, 1H, ³*J* = 8.8 Hz, ⁴*J* = 1.3 Hz, H-4") ; 6.64-6.77 ABX signal (BX part, m, 2H, H-3' and H-5'); ABX signal (A part, 1H, $\delta_A =$ 7.85, *J*_{AB} = 9.7 Hz, H-6'), 10.25 (s, 1H, H-1). - ¹³C **NMR** (CDCl₃ - 50MHz) : $\delta = -4.52$ [Si(CH₃)₂], 2.14 (C-7"), 18.33 [SiC(CH₃)₃], 22.91 (CH₃), 25.86 [SiC(CH₃)₃], 40.10 [N(CH₃)₂], 63.57 (C-5"); 91.55-92.12-94.35 (C-1", 2", 6"), 111.90 (C-5'), 114.43 (C-3'), 119.82 (C-3"), 124.81-128.08 (C-1', 2'), 129.38 (C-6'), 137.00 (C-4"), 153.46 (C-4'), 189.42 (C-1).

- microanalysis : % C (th. = 54.43, exp. = 54.56), % H (th. = 5.96, exp. = 6.02), % N (th. = 2.76, exp. = 2.73).

539